News

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...
Here's what investors should know. On May 27, Eli Lilly announced it would dish out $1 billion in cash to acquire SiteOne Therapeutics, a privately held biotech. The key asset from this ...
Meanwhile, Eli Lilly has also made a strategic move by agreeing to acquire SiteOne Therapeutics in a deal valued at up to $1 billion. This acquisition aims to enhance Lilly’s non-opioid pain ...
Meanwhile, UBS maintained a Buy rating on Eli Lilly, setting a price target of $1,050, and BMO Capital reiterated an Outperform rating with a $900 price target following the SiteOne deal.
Meanwhile, Eli Lilly has also made a strategic move by agreeing to acquire SiteOne Therapeutics in a deal valued at up to $1 billion. This acquisition aims to enhance Lilly’s non-opioid pain ...
Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other ...
Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...